NewsBite

‘A victim of its own success’: Inside the great Ozempic shortage

‘A victim of its own success’: Inside the great Ozempic shortage

The drug is approved in Australia to treat type 2 diabetes but people have flocked to it for weight loss. That’s raising some hard questions about who should receive it and why.

The world has fallen in love with Ozempic and its sister treatment, Wegovy.

Demand for these drugs has been so intense there is now a global shortage and regulators are cautioning people against buying fakes online. Lack of supply also has given rise to conflict and controversy about who should receive these injectable drugs.

Loading...

Read More

Jill Margo
Jill MargoSenior writerJill Margo was a senior writer at The Australian Financial Review.

Latest In Health & education

Fetching latest articles

Original URL: https://www.afr.com/policy/health-and-education/a-victim-of-its-own-success-inside-the-great-ozempic-shortage-20230525-p5db8w